ERBB2 and breast cancer: However, there is substantial preclinical and clinical evidence that HER1 and HER3 not only have negative prognostic impact on the course and outcome of breast cancer disease but also impair the therapeutic efficiency of an anti-HER2 targeting of HER2-positive breast cancer, predominantly carried out with trastuzumab.